A Study of Venetoclax plus Chemotherapy for Newly Diagnosed Acute Lymphoblastic Leukemia


Full Title

Venetoclax in Combination with Asparaginase-Containing Pediatric-Inspired Chemotherapy in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia


Standard treatments for adults newly diagnosed with acute lymphoblastic leukemia (ALL) include a combination of different chemotherapy drugs that are routinely used to treat ALL in children. Researchers think that adding venetoclax to these chemotherapy drugs may be an effective treatment for adults with ALL.

Venetoclax is designed to block BCL-2, a protein that helps cancer cells survive. By targeting BCL-2, venetoclax may cause cancer cells to die. Researchers are doing this study to see if combining venetoclax with several different standard chemotherapy drugs used to treat ALL in children will be safe and effective in adults age 60 and under with previously untreated ALL.

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must be newly diagnosed with T-cell or B-cell ALL and may not have received any prior treatment.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people ages 18-60.


For more information and to ask about eligibility for this study, please contact the office of Dr. Jae Park at 646-608-3743.




Phase 0 (very small research study)



ClinicalTrials.gov ID